证券代码：688626 证券简称：翔宇医疗 公告编号：2023-046 河南翔宇医疗设备股份有限公司 关于以集中竞价交易方式回购公司股份的 回购报告书 相关股东是否存在减持计划 2023 年 4 月 20 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《河南翔宇医疗设备股份有限公司关于股东及其一致行动人减持股份计划公告》 （公告编号：2023-009），嘉兴济峰一号股权投资合伙企业（有限合伙）、苏州 济峰股权投资合伙企业（有限合伙）、福州济峰股权投资合伙企业（有限合伙）， 因具有股权关联关系，股权合并计算后，属于持股 5%以上的股东，因自身资金 需求，拟通过集中竞价交易或大宗交易的方式减持其所持有的公司股份合计不超 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 河南翔宇医疗设备股份有限公司（以下简称"公司"）拟通过集中竞价 交易方式回购公司已发行的人民币普通股（A 股），主要内容如下： 1、拟回购股份的用途：本次回购的股份将在未来适宜时机拟用于股权激励 或员工持股计划，或用于转换上市 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2023-045 河南翔宇医疗设备股份有限公司 关于以集中竞价交易方式回购公司股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 河南翔宇医疗设备股份有限公司（以下简称"公司"）拟使用超募资金 以集中竞价交易的方式回购公司股份，主要内容如下： 1、拟回购股份的用途：本次回购的股份将在未来适宜时机拟用于股权激励 或员工持股计划，或用于转换上市公司发行的可转换为股票的公司债券。若公司 未能在股份回购实施结果暨股份变动公告日后三年内实施上述用途，未使用部分 股份将被注销； 2、回购规模：回购资金总额不低于人民币 8,000 万元（含），不超过人民 币 16,000 万元（含）； 3、回购价格：不超过人民币 65.00 元/股（含），该价格不高于公司董事会 通过回购决议前 30 个交易日公司股票交易均价的 150%； 4、回购期限：自董事会审议通过本次回购方案之日起 12 个月内； 5、回购资金来源：本次回购股份的资金来源为公司首发超募资金。 6、相 ...

河南翔宇医疗设备股份有限公司 第二届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688626 证券简称：翔宇医疗 公告编号：2023-044 一、董事会会议召开情况 河南翔宇医疗设备股份有限公司（以下简称"公司"）第二届董事会第十一 次会议于 2023 年 8 月 10 日在公司会议室以现场结合通讯的方式召开。会议通知 于 2023 年 8 月 10 日送达各位董事，全体董事一致同意豁免本次会议通知时间要 求。本次会议应出席董事 5 人,实际出席董事 5 人,其中独立董事叶忠明先生、王 珏女士以通讯方式出席会议。会议由董事长何永正先生召集并主持,公司监事及 高级管理人员列席会议。会议的召开及表决程序符合有关法律、行政法规、部门 规章和《公司章程》的规定。 二、董事会会议审议情况 经与会董事投票表决，本次会议审议并通过了以下议案： 河南翔宇医疗设备股份有限公司董事会 2023 年 8 月 11 日 2 表决结果：同意 5 票，反对 0 票，弃权 0 票。 独立董事对此议案发表了明确同 ...

2、公司本次股份回购资金总额不低于人民币 8,000 万元（含），不超过人 民币 16,000万元(含),拟用于本次回购的资金来源为公司首发超募资金,不 会对公司的经营、财务和未来发展产生重大影响,公司有能力支付回购价款。回 购后公司的股权分布情况符合上市公司的条件,不会影响公司的上市地位。 3、公司本次回购股份的实施,有利于维护公司和股东利益,有利于完善公 司长效激励机制,充分调动公司员工的积极性,有利于促进公司健康可持续发展, 公司本次股份回购具有必要性。 河南翔宇医疗设备股份有限公司 独立董事关于第二届董事会第十一次会议相关事项的 独立意见 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民 共和国证券法》(以下简称"《证券法》")、《上市公司独立董事规则》等法 律法规及《河南翔宇医疗设备股份有限公司章程》(以下简称"《公司章程》")、 《河南翔宇医疗设备股份有限公司独立董事工作制度》的有关规定,我们作为河 南翔宇医疗设备股份有限公司(以下简称"公司")的独立董事,对公司第二届 董事会第十一次会议审议的相关议案进行了审阅,基于独立客观的立场,本着负 责审慎的态度,现就董事会相关事项发表如 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2023-043 二、提议人提议回购股份的原因和目的 河南翔宇医疗设备股份有限公司 关于公司实际控制人提议公司回购股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 河南翔宇医疗设备股份有限公司（以下简称"公司"）董事会于 2023 年 8 月 10 日收到公司实际控制人何永正、郭军玲夫妇递交的《关于提议河南翔 宇医疗设备股份有限公司回购公司股份的函》。何永正、郭军玲夫妇提议公司以 首发超募资金通过上海证券交易所交易系统以集中竞价交易方式回购公司已发 行的部分人民币普通股（A 股）股票，具体内容如下： 一、提议人的基本情况及提议时间 1、提议人：公司实际控制人何永正、郭军玲夫妇 2、提议时间：2023 年 8 月 10 日 公司实际控制人何永正、郭军玲夫妇基于对公司未来发展的信心和对公司价 值的高度认可，为建立、完善公司长效激励机制，充分调动公司员工的积极性， 提高团队凝聚力和竞争力，有效地将股东利益、公司利益和员工利益紧密结合在 一起。经综合考 ...

上海市通力律师事务所 关于河南翔宇医疗设备股份有限公司 2023 年第一次临时股东大会的法律意见书 致:河南翔宇医疗设备股份有限公司 上海市通力律师事务所(以下简称"本所")接受河南翔宇医疗设备股份有限公司(以下 简称"公司")的委托,指派本所高云、杜颖律师(以下简称"本所律师")根据《中华人民共 和国公司法》《中华人民共和国证券法》《上市公司股东大会规则》等法律法规和规范性文 件(以下统称"法律法规")及《河南翔宇医疗设备股份有限公司章程》(以下简称"公司章 程")的规定就公司 2023 年第一次临时股东大会(以下简称"本次股东大会")相关事宜出 具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以了 核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中的所有 签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、完整和有 效的,且文件材料为副本或复印件的,其与原件一致和相符。 西走 HONG KONG 伦敦 LONDON 在此基础上,本所律师出具法律意见如下: 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股东大会 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 12 | | --- | --- | | 普通股股东人数 | 12 | | 2、出席会议的股东所持有的表决权数量 | 123,886,640 | | 普通股股东所持有表决权数量 | 123,886,640 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 78.6332 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 78.6332 | 证券代码：688626 证券简称：翔宇医疗 公告编号：2023-041 河南翔宇医疗设备股份有限公司 2023 年第一次临时股东大会决议公告 注：公司表决权数量不含截至股权登记日公司已回购股份的数量。 （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2023-042 河南翔宇医疗设备股份有限公司 关于 2023 年限制性股票激励计划内幕信息知情人 及激励对象买卖公司股票情况的自查报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 河南翔宇医疗设备股份有限公司（以下简称"公司"）于 2023 年 7 月 19 日召开第二届董事会第九次会议、第二届监事会第六次会议，审议通过了《关于 <公司 2023 年限制性股票激励计划（草案）>及其摘要的议案》等议案，并于 2023 年 7 月 20 日在上海证券交易所网站（www.sse.com.cn）披露了相关公告。 根据《上市公司信息披露管理办法》、《上市公司股权激励管理办法》、《上 海证券交易所科创板股票上市规则》、《科创板上市公司自律监管指南第 4 号 ——股权激励信息披露》等法律、法规及规范性文件的要求，公司通过向中国证 券登记结算有限责任公司上海分公司对 2023 年限制性股票激励计划（以下简称 "本激励计划"）的内幕信息知情人及激励对象在本激励计划草案公开披露前 6 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with a total revenue of 500 million RMB, representing a 20% year-over-year growth[1]. - The company achieved operating revenue of CNY 334.76 million in the first half of 2023, representing a 51.55% increase compared to the same period last year[21]. - Net profit attributable to shareholders reached CNY 107.61 million, up 169.00% year-on-year, while the net profit after deducting non-recurring gains and losses was CNY 94.77 million, an increase of 269.41%[23]. - The net cash flow from operating activities was CNY 100.55 million, a significant increase of 450.10% compared to the previous year[23]. - Basic earnings per share rose to CNY 0.68, reflecting a 172.00% increase from CNY 0.25 in the same period last year[22]. - The company achieved a revenue of 2,352.66 million, with a net profit of 164.99 million, marking a significant increase from the previous period[61]. - The company achieved a revenue of 2,432.43 million, with a year-on-year growth of 667.58 million, representing a 38% increase[64]. - The company reported a revenue of 37,589.55 million RMB in the first half of 2023, a significant increase from 29,457.40 million RMB in the same period last year, representing a growth of approximately 27.3%[69]. Market Expansion and Strategy - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 25% compared to the first half[1]. - Market expansion plans include entering two new provinces, which are projected to increase market share by 10%[1]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence, with potential targets identified[1]. - The company aims to improve its market position through strategic partnerships and potential acquisitions in the rehabilitation sector[15]. - The company plans to increase its market share by targeting both domestic and international markets for its rehabilitation solutions[15]. - The company is actively pursuing market expansion and product diversification to enhance its competitive edge in the rehabilitation and nursing sectors[62]. Research and Development - The company is investing in R&D, with a budget increase of 30% for new technology development aimed at enhancing product efficiency[1]. - Research and development expenses accounted for 14.18% of operating revenue, a decrease of 5.53 percentage points compared to the previous year[22]. - The company has established a comprehensive R&D process that adheres to ISO13485 standards, ensuring risk control and feasibility throughout product development[44]. - The company has accumulated a significant number of proprietary core technologies over 20 years, with new applications introduced during the reporting period[50]. - The company has developed advanced technologies such as high-pressure pulse control and three-dimensional dynamic feedback analysis for its product lines[50][51]. - The company has developed over 30 specialized rehabilitation solutions, including pain rehabilitation, neurological rehabilitation, and postoperative rehabilitation solutions, addressing various clinical needs[80]. - The company has a strong focus on technology research and development, achieving modular and component-based construction to quickly meet clinical demands through integrated product development[81]. Product Development and Offerings - New product launches are expected to contribute an additional 100 million RMB in revenue by the end of the year[1]. - The company offers over 500 types of rehabilitation medical devices across 20 major series, providing a comprehensive product structure in the rehabilitation medical device field[39]. - The product line includes over 10 types of physical therapy technologies, such as shock wave therapy and biofeedback systems, aimed at improving patient outcomes[41]. - The company has developed a gait training system that incorporates intelligent control technology, enhancing rehabilitation for patients with various conditions[62]. - The company is enhancing its product offerings in postpartum rehabilitation, with a comprehensive product system for related therapies[66]. Operational Efficiency - The management highlighted a focus on improving operational efficiency, aiming for a 15% reduction in production costs by the end of the fiscal year[1]. - The company has established partnerships with three new distributors to enhance its distribution network, expected to boost sales by 20%[1]. - The company operates a complete system for product research and development, procurement, production, sales, and service in the rehabilitation medical industry[43]. - The company has a robust quality control capability and extensive production organization experience in the rehabilitation medical device sector[83]. Risk Management - Risk factors related to supply chain disruptions have been acknowledged, with mitigation strategies in place to minimize impact[1]. - The company faces risks related to technology innovation and competition in the rehabilitation equipment industry[96][97]. Corporate Governance and Compliance - The company has committed to transparency in related party transactions and will disclose necessary information in accordance with regulations[153]. - The company has established a commitment to ensure that any share reduction does not adversely affect its governance structure and ongoing operations[138]. - The company is focused on maintaining a strong corporate governance structure to support its IPO efforts[145]. Community Engagement and Environmental Responsibility - The company invested 187,500 RMB in environmental protection during the reporting period[125]. - The company provided 12,500 RMB in scholarships to 21 employees' children and one local impoverished college student, and donated 70,000 RMB for local road repairs[133].

Financial Performance - The company's operating revenue for 2022 was CNY 488.53 million, a decrease of 6.68% compared to CNY 523.50 million in 2021[23]. - The net profit attributable to shareholders for 2022 was CNY 12.55 million, down 37.85% from CNY 20.19 million in 2021[24]. - The basic earnings per share decreased by 41.48% to CNY 0.79 in 2022 from CNY 1.35 in 2021[24]. - The company's net profit attributable to the parent company was 125.47 million yuan, down 37.85% year-on-year, while the net profit after deducting non-recurring gains and losses was 77.79 million yuan, a decline of 48.76%[34]. - The company's total revenue for the year was CNY 483,871,268.14, representing a year-on-year decrease of 6.19%[150]. - The gross profit margin for the main business was 66.17%, a decrease of 2.01 percentage points compared to the previous year, primarily due to changes in the sales product structure[147]. Shareholder Returns - The proposed cash dividend for 2022 is CNY 2.40 per 10 shares, totaling CNY 37,812,000, which accounts for 30.14% of the net profit attributable to shareholders[5]. - The company repurchased shares amounting to CNY 73,270,345.21, representing 58.40% of the net profit attributable to shareholders for 2022[6]. - The total cash dividends distributed, including the repurchased shares, amount to CNY 111,082,345.21, which is 88.54% of the net profit attributable to shareholders for 2022[6]. Research and Development - The company's R&D expenses accounted for 18.92% of operating revenue, an increase of 5.81 percentage points compared to 13.11% in 2021[24]. - R&D expenses amounted to 92.41 million yuan, an increase of 34.70% year-on-year, accounting for 18.92% of total revenue, up 5.81 percentage points from the previous year[35]. - The total number of R&D personnel reached 434, accounting for 25.48% of the total workforce, with ongoing expansion of R&D centers in various cities[36]. - The company has obtained a total of 1,251 patents, with 402 patent applications submitted during the reporting period, including 81 invention patents[37]. - The company has developed advanced core technologies, including intelligent feedback systems for rehabilitation, which enhance patient safety and treatment effectiveness[92]. Market Position and Strategy - The company is positioned to address the growing demand for rehabilitation services, particularly for chronic and elderly patients[15]. - The rehabilitation medical device industry in China is expected to exceed 1 trillion yuan in main business revenue from 2021 to 2023[61]. - The average annual growth rate of the rehabilitation medical device industry is approximately 20%[64]. - The company aims to improve patient experience by reducing product delivery times through pre-production of high-demand components[57]. - The company is focusing on expanding its market presence through innovative product offerings and strategic partnerships in the rehabilitation sector[54]. Product Development and Innovation - The company launched a series of new rehabilitation products, including a comprehensive physical therapy system and a biofeedback-assisted electrical stimulation device, enhancing its product portfolio[44]. - The company has developed over 500 proprietary rehabilitation products across 20 categories, establishing a comprehensive product system in the rehabilitation medical device sector[51]. - The company has developed a comprehensive physical therapy system that integrates multiple treatment modalities to address common clinical conditions[53]. - The company is focusing on the development of traditional Chinese medicine rehabilitation equipment, which is expected to expand its market presence in hospitals and specialized clinics[180]. - The company is developing integrated solutions for over 30 clinical specialties, utilizing smart technology and ergonomic design to create a connected rehabilitation medical space[192]. Risk Management - The company has detailed risk factors in the management discussion and analysis section, advising investors to be cautious of investment risks[4]. - The company faces risks related to technological innovation and competition in the rapidly developing rehabilitation equipment industry[132]. - The company is exposed to industry policy changes, particularly in the rehabilitation medical device sector, which could impact pricing and bidding outcomes[139]. - The competitive landscape in the rehabilitation device market is intensifying, with potential risks to market share if growth does not meet expectations[140]. Corporate Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company has not experienced any inability of the majority of directors to ensure the authenticity and completeness of the annual report[8]. Awards and Recognition - The company was recognized as a "National Technology Innovation Demonstration Enterprise" and received the Henan Provincial Governor Quality Award in 2022[70]. - The company received multiple awards for its technological innovations, including first prize at the China Rehabilitation Medicine Association Science and Technology Award for three consecutive years[40]. - The company has been recognized as a national high-tech enterprise and a model production base for traditional Chinese medicine diagnostic equipment, reflecting its industry leadership[121].